BIO-TECHNE (TECH) Downgraded to Buy at ValuEngine

ValuEngine downgraded shares of BIO-TECHNE (NASDAQ:TECH) from a strong-buy rating to a buy rating in a research note released on Tuesday, ValuEngine reports.

Several other equities research analysts have also commented on TECH. BidaskClub raised shares of BIO-TECHNE from a buy rating to a strong-buy rating in a report on Wednesday, April 10th. Zacks Investment Research raised shares of BIO-TECHNE from a sell rating to a hold rating in a report on Saturday, January 5th. Argus reaffirmed a buy rating on shares of BIO-TECHNE in a report on Monday, March 4th. Craig Hallum reaffirmed a hold rating and issued a $179.00 price target (up from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. Finally, Stephens raised shares of BIO-TECHNE from an equal weight rating to an overweight rating and set a $180.00 price target on the stock in a report on Monday, January 14th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $188.13.

NASDAQ:TECH opened at $195.27 on Tuesday. BIO-TECHNE has a one year low of $132.75 and a one year high of $206.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.31 and a current ratio of 4.35. The firm has a market capitalization of $7.64 billion, a price-to-earnings ratio of 47.98, a price-to-earnings-growth ratio of 4.56 and a beta of 1.25.

BIO-TECHNE (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, February 5th. The biotechnology company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.98 by $0.08. BIO-TECHNE had a net margin of 14.02% and a return on equity of 13.90%. The company had revenue of $174.50 million for the quarter, compared to analyst estimates of $171.39 million. During the same period in the prior year, the company earned $1.02 earnings per share. The firm’s revenue was up 13.2% on a year-over-year basis. Sell-side analysts anticipate that BIO-TECHNE will post 3.68 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Executive Wealth Management LLC acquired a new position in shares of BIO-TECHNE in the fourth quarter worth about $38,000. First Hawaiian Bank raised its position in shares of BIO-TECHNE by 59.9% in the first quarter. First Hawaiian Bank now owns 219 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 82 shares during the period. Portfolio Solutions LLC acquired a new position in shares of BIO-TECHNE in the fourth quarter worth about $50,000. We Are One Seven LLC acquired a new position in shares of BIO-TECHNE in the fourth quarter worth about $121,000. Finally, ETF Managers Group LLC raised its position in shares of BIO-TECHNE by 18.1% in the fourth quarter. ETF Managers Group LLC now owns 869 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 133 shares during the period. Institutional investors and hedge funds own 93.94% of the company’s stock.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Story: How does inflation affect different investments?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit